Human T-lymphotropic virus-1 infection among Latin American pregnant women living in Spain.

Breastfeeding HTLV-1 Migration Pregnant women Vertical transmission

Journal

IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 02 10 2023
revised: 15 11 2023
accepted: 16 11 2023
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: epublish

Résumé

Human T-lymphotropic virus (HTLV) antenatal screening is not mandatory in Spain. Surveys conducted decades ago reported HTLV-1 seroprevalence rates of 0.2% among foreign pregnant women in Spain. The migrant flow to Spain from HTLV-1 endemic regions in Latin America and sub-Saharan Africa has increased during the last decade. Currently, 25% of pregnant women in Spain are foreigners. From January 2021 to October 2023 a cross-sectional study was carried out in all consecutive pregnant women attended at eleven Spanish clinics. A commercial enzyme immunoassay (EIA) was used for screening of serum HTLV-1/2 antibodies. Reactive samples were confirmed by immunoblot. A total of 9813 pregnant women with a median age of 34 years-old were examined. Native Spaniards were 6977 (76.5%). Of 2147 foreigners (23.5%), 903566 (9.9%) were Latin Americans, 416 (4.5%) North Africans, 293 (3.2%) from Romania, and 196 (2.1%) from sub-Saharan Africa. A total of 47 samples were EIA reactive but only five were confirmed as HTLV-1 positive using immunoblot. Infected women came from Paraguay, Colombia, the Dominican Republic, Venezuela and Peru. All but one were primigravida, with ages ranging from 20 to 33 years-old. One was HIV-1 positive, and another was infected with The overall seroprevalence for HTLV-1 among pregnant women in Spain is 0.05% but rises ten-fold (0.55%) among Latin Americans. This rate is higher than in surveys conducted decades ago. Our results support that anti-HTLV testing should be part of antenatal screening in Spain in pregnant women coming from Latin America, as it is already done with Chagas disease.

Identifiants

pubmed: 38304758
doi: 10.1016/j.ijregi.2023.11.010
pii: S2772-7076(23)00118-2
pmc: PMC10831283
doi:

Types de publication

Journal Article

Langues

eng

Pagination

146-149

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors have completed the information regarding conflicts of interest in the requested documentation and have no conflicts of interest to disclose.

Auteurs

Begoña Encinas (B)

Gynecology & Obstetrics Department, Puerta de Hierro University Hospital, Madrid, Spain.

Rafael Benito (R)

Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Silvia Rojo (S)

Microbiology Department, Hospital Clínico Universitario, Valladolid, Spain.

Gabriel Reina (G)

Microbiology Department, Clínica Universidad de Navarra, Pamplona, Spain.

Natalia Montiel (N)

Microbiology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain.

Antonio Aguilera (A)

Microbiology Department, University of Santiago, Santiago de Compostela, Spain.

José María Eiros (JM)

Microbiology Department, Rio Hortega University Hospital, Valladolid, Spain.

Juan García-Costa (J)

Microbiology Department, Complejo Hospitalario de Ourense, Ourense, Spain.

Diego Ortega (D)

Microbiology Department, Hospital Miguel Servet, Zaragoza, Spain.

Irene Arco (I)

Microbiology Department, General University Hospital of Alicante, Pintor Baeza, Alicante, Spain.

Araceli Hernánez-Batancor (A)

Microbioligy Department, Hospital insular Unidad De Traslados, Avenida Maritima del Sur, Las Palmas de Gran Canaria, Spain.

Vicente Soriano (V)

International University of La Rioja (UNIR) Health Sciences School & Medical Center, Madrid, Spain.

Carmen de Mendoza (C)

Puerta de Hierro University Hospital & Research Foundation-IDIPHISA, Madrid, Spain.

Classifications MeSH